Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis

Singh, Bandana; Cui, Kui; Eisa-Beygi, Shahram; Zhu, Bo; Cowan, Douglas B.; Shi, Jinjun; Wang, Da-Zhi; Liu, Zhenguo; Bischoff, Joyce; Chen, Hong

doi:10.1016/j.vph.2024.107368

Cited by 4 publications

(3 citation statements)

References 216 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atherosclerosis, a primary contributor to cardiovascular disease, is characterized by the gradual buildup of arterial plaque within the walls of the arteries [1,3,6]. Regulation of bile acid metabolism is an effective approach to preventing hyperlipidemia and AS Spearman correlation analyses showed significant associations between the abundances of taxa and bile acid-related indices (Figures S1 and S2).…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Atherosclerosis (AS), the leading cause of cardiovascular disease, is characterized by thickening of the arterial intima, the formation of foam cells, the development of plaque on vessel walls, and the potential for stenosis or complete blockage of the lumen [1,2]. The total cholesterol level is elevated, which is the central risk factor for AS [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Neoagarotetraose Alleviates Atherosclerosis via Modulating Cholesterol and Bile Acid Metabolism in ApoE−/− Mice

Li,

Yang,

Liu

et al. 2024

Nutrients

View full text Add to dashboard Cite

Atherosclerosis is closely associated with metabolic disorders such as cholesterol accumulation, bile acid metabolism, and gut dysbiosis. Neoagarotetraose supplementation has been shown to inhibit obesity and alleviate type 2 diabetes, but its effects on modulating the development of atherosclerosis remain unexplored. Therefore, the present study was conducted to investigate the protective effects and potential mechanisms of neoagarotetraose on high-fat, high-cholesterol diet (HFHCD)-induced atherosclerosis in ApoE−/− mice. The results showed that neoagarotetraose supplementation decreased the atherosclerotic lesion area by 50.1% and the aortic arch lesion size by 80.4% compared to the HFHCD group. Furthermore, neoagarotetraose supplementation led to a significant reduction in hepatic lipid content, particularly non-high-density lipoprotein cholesterol. It also resulted in a substantial increase in total bile acid content in both urine and fecal samples by 3.0-fold and 38.7%, respectively. Moreover, neoagarotetraose supplementation effectively downregulated the intestinal farnesoid X receptor by 35.8% and modulated the expressions of its associated genes in both the liver and intestine. In addition, correlation analysis revealed strong associations between gut microbiota composition and fecal bile acid levels. These findings highlight the role of gut microbiota in neoagarotetraose-mitigating atherosclerosis in HFHCD-fed ApoE−/− mice. This study indicates the potential of neoagarotetraose as a functional dietary supplement for the prevention of atherosclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neoagarotetraose Alleviates Atherosclerosis via Modulating Cholesterol and Bile Acid Metabolism in ApoE−/− Mice

Li,

Yang,

Liu

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

Advanced Applications of Nanomaterials in Atherosclerosis Diagnosis and Treatment: Challenges and Future Prospects

Tong,

Wang,

Zhang

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Atherosclerosis-induced coronary artery disease is a major cause of cardiovascular mortality. Clinically, conservative treatment strategies for atherosclerosis still focus on lifestyle interventions and the use of lipid-lowering and anticoagulant medications. Despite achieving some therapeutic effects, these approaches are limited by low bioavailability, long intervention periods, and significant side effects. With the advancement of nanotechnology, nanomaterials have demonstrated extraordinary potential in the biomedical field. Their excellent biocompatibility, surface modifiability, and high targeting capability not only enable efficient diagnosis of plaque progression but also allow precise drug delivery within atherosclerotic plaques, significantly enhancing drug bioavailability and reducing systemic side effects. Here, we systematically review the current research progress of nanomaterials in the field of atherosclerosis to summarize not only the types of nanomaterials but also their applications in both the diagnosis and treatment of atherosclerosis. Notably, in the context of plaque therapy, we provide a comprehensive overview of current nanomaterial applications based on their targeted therapeutic systems for different cell types within plaques. Additionally, we address the persistent challenge of clinical translation of nanomaterials by summarizing current issues and providing directions for innovation and improvement in nanomaterial design. Overall, we believe that this review systematically summarizes the applications and challenges of biomedical nanomaterials in atherosclerosis diagnosis and therapy, thereby offering insights and references for the development of therapeutic materials for atherosclerosis.

show abstract

Histone Deacetylase 3: A New Target for the Treatment of Abdominal Aortic Aneurysm?

刘

2024

JCPM

View full text Add to dashboard Cite

Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis

Cited by 4 publications

References 216 publications

Neoagarotetraose Alleviates Atherosclerosis via Modulating Cholesterol and Bile Acid Metabolism in ApoE−/− Mice

Neoagarotetraose Alleviates Atherosclerosis via Modulating Cholesterol and Bile Acid Metabolism in ApoE−/− Mice

Advanced Applications of Nanomaterials in Atherosclerosis Diagnosis and Treatment: Challenges and Future Prospects

Histone Deacetylase 3: A New Target for the Treatment of Abdominal Aortic Aneurysm?

Contact Info

Product

Resources

About